Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
LY3177833, a novel and potent CDC7 (Cell Division Cycle 7-related Protein Kinase) and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively, was extracted from patent US 20140275131 and patent WO 2014143601 A1 compound 4.
Targets |
Cdc7 (IC50 = 3.3 nM); pMCM2 (IC50 = 290 nM)
|
---|---|
ln Vitro |
LY3177833 (10 μM; 4 days) raises the SA-β-gal content in Hep3B cells[2].
|
ln Vivo |
LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) significantly reduces tumors in a dose-dependent manner. Additionally, two weeks after stopping the medication, no discernible tumor growth is seen[1].
|
Cell Assay |
Cell Line: Hep3B cells
Concentration: 10 μM Incubation Time: 4 days Result: Increased the expression of human SA-β-gal. |
Animal Protocol |
Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cells[1]
10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg Oral gavage; twice a day for 2 weeks |
References |
Molecular Formula |
C16H12FN5O
|
---|---|
Molecular Weight |
309.297785758972
|
Exact Mass |
309.10
|
Elemental Analysis |
C, 62.13; H, 3.91; F, 6.14; N, 22.64; O, 5.17
|
CAS # |
1627696-51-8
|
Related CAS # |
LY3177833 monhydrate;1627696-53-0
|
Appearance |
Solid powder
|
SMILES |
C[C@@]1(C2=C(C=C(C=C2)C3=CNN=C3)C(=O)N1)C4=NC=NC=C4F
|
InChi Key |
KNLVLWZENYQYRT-MRXNPFEDSA-N
|
InChi Code |
InChI=1S/C16H12FN5O/c1-16(14-13(17)7-18-8-19-14)12-3-2-9(10-5-20-21-6-10)4-11(12)15(23)22-16/h2-8H,1H3,(H,20,21)(H,22,23)/t16-/m1/s1
|
Chemical Name |
(3R)-3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)-2H-isoindol-1-one
|
Synonyms |
LY-3177833; LY3177833; LY 3177833
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ≥ 30 mg/mL (~97 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2331 mL | 16.1655 mL | 32.3311 mL | |
5 mM | 0.6466 mL | 3.2331 mL | 6.4662 mL | |
10 mM | 0.3233 mL | 1.6166 mL | 3.2331 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.